Related references
Note: Only part of the references are listed.Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: A systematic review
Erik F. Eriksen et al.
BONE (2014)
Clinician's Guide to Prevention and Treatment of Osteoporosis
F. Cosman et al.
OSTEOPOROSIS INTERNATIONAL (2014)
Treatment of osteoporosis in men with bisphosphonates: rationale and latest evidence
Ie-Wen Sim et al.
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2013)
Is There Really No Benefit of Vertebroplasty for Osteoporotic Vertebral Fractures? A Meta-analysis
Ming-Min Shi et al.
CLINICAL ORTHOPAEDICS AND RELATED RESEARCH (2012)
Fracture Risk and Zoledronic Acid Therapy in Men with Osteoporosis
Steven Boonen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Surgical therapy of osteoporotic vertebral body fractures
D. Boluki
ZEITSCHRIFT FUR RHEUMATOLOGIE (2011)
Efficacy and safety of monthly ibandronate in men with low bone density
Eric S. Orwoll et al.
BONE (2010)
The effects of weekly alendronate therapy in Taiwanese males with osteoporosis
Jawl-Shan Hwang et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2010)
Efficacy and Safety of a Once-Yearly i.v. Infusion of Zoledronic Acid 5 mg Versus a Once-Weekly 70-mg Oral Alendronate in the Treatment of Male Osteoporosis: A Randomized, Multicenter, Double-Blind, Active-Controlled Study
Eric S. Orwoll et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Once-Weekly Risedronate in Men With Osteoporosis: Results of a 2-Year, Placebo-Controlled, Double-Blind, Multicenter Study
Steven Boonen et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
2009 Updated Method Guidelines for Systematic Reviews in the Cochrane Back Review Group
Andrea D. Furlan et al.
SPINE (2009)
被撤回的出版物: Comparison of the Effects of Alendronate and Alfacalcidol on Hip Bone Mineral Density and Bone Turnover in Japanese Men Having Osteoporosis or Osteopenia with Clinical Risk Factors for Fractures (Retracted article. See vol. 64, pg. 228, 2023)
Jun Iwamoto et al.
YONSEI MEDICAL JOURNAL (2009)
Zoledronic acid and clinical fractures and mortality after hip fracture
Kenneth W. Lyles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
Dennis M. Black et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study
JY Reginster et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study
JD Ringe et al.
RHEUMATOLOGY INTERNATIONAL (2006)
Does Alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women
AM Sawka et al.
BMC MUSCULOSKELETAL DISORDERS (2005)
Systems for grading the quality of evidence and the strength of recommendations II:: Pilot study of a new system -: art. no. 25
D Atkins et al.
BMC HEALTH SERVICES RESEARCH (2005)
Male osteoporosis - New trends in diagnosis and therapy
HK Kamel
DRUGS & AGING (2005)
Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study
JD Ringe et al.
RHEUMATOLOGY INTERNATIONAL (2004)
Measuring inconsistency in meta-analyses
JPT Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)
Alendronate treatment in men with primary osteoporosis: A three-year longitudinal study
S Gonnelli et al.
CALCIFIED TISSUE INTERNATIONAL (2003)
The prevalence of osteoporosis: Gender and racial comparison
LJ Melton
CALCIFIED TISSUE INTERNATIONAL (2001)
Effect of risedronate on the risk of hip fracture in elderly women
MR McClung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Alendronate for the treatment of osteoporosis in men
E Orwoll et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis
JY Reginster et al.
OSTEOPOROSIS INTERNATIONAL (2000)
Share Paper
